Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BIVINASDAQ:GLYCNASDAQ:NRSNNASDAQ:RWOD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIVIBioVie$1.09+5.8%$1.01$0.62▼$7.50$20.24M0.771.84 million shs188,318 shsGLYCGlycoMimetics$0.16-6.6%$21.02$14.06▼$63.00$10.00M1.6268,818 shs1.05 million shsNRSNNeuroSense Therapeutics$2.45+2.1%$1.45$0.51▼$2.60$33.48M1.62274,859 shs325,122 shsRWODRedwoods Acquisition$0.73$0.93$2.22▼$13.10$3.75MN/A108,185 shs22,784 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIVIBioVie0.00%-8.40%+4.81%-2.68%+142.87%GLYCGlycoMimetics0.00%-99.07%-99.41%-99.43%-99.36%NRSNNeuroSense Therapeutics0.00%+2.94%+50.31%+128.97%+166.30%RWODRedwoods Acquisition0.00%0.00%0.00%0.00%-87.86%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBIVIBioVie2.2731 of 5 stars3.83.00.00.00.00.00.6GLYCGlycoMimetics1.776 of 5 stars0.03.00.04.63.11.70.0NRSNNeuroSense Therapeutics1.823 of 5 stars3.53.00.00.00.61.70.0RWODRedwoods AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIVIBioVie 3.50Strong Buy$3.00175.23% UpsideGLYCGlycoMimetics 2.50Moderate BuyN/AN/ANRSNNeuroSense Therapeutics 3.00Buy$14.00471.43% UpsideRWODRedwoods Acquisition 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest RWOD, BIVI, GLYC, and NRSN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025NRSNNeuroSense TherapeuticsD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/12/2025NRSNNeuroSense TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.003/21/2025GLYCGlycoMimeticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIVIBioVieN/AN/AN/AN/A$2.54 per shareN/AGLYCGlycoMimetics$10K1,000.25N/AN/A$0.08 per share1.94NRSNNeuroSense TherapeuticsN/AN/AN/AN/A$0.19 per shareN/ARWODRedwoods AcquisitionN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIVIBioVie-$32.12M-$7.91N/A∞N/AN/A-100.88%-78.49%8/21/2025 (Estimated)GLYCGlycoMimetics-$37.88M-$0.46N/AN/AN/AN/A-230.74%-177.39%8/6/2025 (Estimated)NRSNNeuroSense Therapeutics-$10.21M-$0.54N/A∞N/AN/AN/A-445.40%6/24/2025 (Estimated)RWODRedwoods AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/ALatest RWOD, BIVI, GLYC, and NRSN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/24/2025Q1 2025NRSNNeuroSense Therapeutics-$0.13N/AN/AN/AN/AN/A5/14/2025Q1 2025GLYCGlycoMimetics-$5.00-$4.00+$1.00-$0.04N/AN/A5/12/2025Q3 2025BIVIBioVie-$0.32-$0.15+$0.17-$0.15N/AN/A4/7/2025Q4 2024NRSNNeuroSense Therapeutics-$0.12-$0.06+$0.06-$0.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBIVIBioVieN/AN/AN/AN/AN/AGLYCGlycoMimeticsN/AN/AN/AN/AN/ANRSNNeuroSense TherapeuticsN/AN/AN/AN/AN/ARWODRedwoods AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIVIBioVieN/A9.319.31GLYCGlycoMimeticsN/A1.921.92NRSNNeuroSense TherapeuticsN/A2.212.21RWODRedwoods AcquisitionN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIVIBioVie4.59%GLYCGlycoMimetics75.19%NRSNNeuroSense Therapeutics1.04%RWODRedwoods Acquisition20.07%Insider OwnershipCompanyInsider OwnershipBIVIBioVie2.39%GLYCGlycoMimetics8.70%NRSNNeuroSense Therapeutics27.40%RWODRedwoods Acquisition2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBIVIBioVie1018.57 million18.13 millionNo DataGLYCGlycoMimetics5064.53 million58.90 millionOptionableNRSNNeuroSense Therapeutics1013.67 million9.92 millionNot OptionableRWODRedwoods AcquisitionN/A5.17 million5.06 millionNot OptionableRWOD, BIVI, GLYC, and NRSN HeadlinesRecent News About These CompaniesCal Redwood Acquisition Corp. Announces Pricing of $200 Million Initial Public OfferingMay 23, 2025 | bakersfield.comRedwood Holdings Limited vow to return Reading ‘to its rightful place in English football’ after completing takeoverMay 15, 2025 | nytimes.comRedwood Services Makes 19th AcquisitionMay 15, 2025 | achrnews.comRedwood Announces Investment by Atlas PartnersMay 9, 2025 | achrnews.comRedwood Materials preps for expansion spree with new R&D center in San FranciscoApril 2, 2025 | msn.comBlank-Check Company Cal Redwood Files for IPOMarch 4, 2025 | marketwatch.comEnvironmental Groups Praise Plan to Conserve Coastal Redwoods, Expand Protected LandFebruary 20, 2025 | sanjoseinside.com$24 million land deal creates 7-mile-long Bay Area corridor of protected redwood forests to the oceanFebruary 12, 2025 | msn.comSave the Redwoods League signs $24 million deal to purchase Monte Rio redwood forest and expand county parkFebruary 12, 2025 | pressdemocrat.com$24 million land deal creates 7-mile long corridor of protected redwood forests to the oceanFebruary 11, 2025 | eastbaytimes.comRedwood Gospel Mission finalizes purchase of former SAY Dream Center in Santa RosaJanuary 5, 2025 | pressdemocrat.comRedwood Empire Whiskey Acquires Luxury Northern California DistilleryDecember 21, 2024 | markets.businessinsider.comAcacia Capital buys Redwood City apartments for $184MNovember 13, 2024 | therealdeal.comRedwood Realty Negotiates $6.6M Sale of Jersey City Apartment BuildingOctober 24, 2024 | rebusinessonline.comSave the Redwoods League acquires 750 acres of Redwood Forest in Sonoma and Mendocino Counties for future parks expansionsOctober 13, 2024 | ukiahdailyjournal.comOne of California's most popular old-growth redwood parks is about to get biggerOctober 11, 2024 | msn.comSave the Redwood League acquires 750 acres of land to expand Montgomery Woods, Armstrong WoodsOctober 11, 2024 | mendovoice.comRedwood Gospel Mission in line to buy former SAY Dream Center campus in Santa RosaOctober 6, 2024 | pressdemocrat.comBMW of North America partners with Redwood MaterialsSeptember 27, 2024 | recyclingtoday.comThree miles of scenic Northern California coastline preserved in major redwoods dealSeptember 12, 2024 | times-standard.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRWOD, BIVI, GLYC, and NRSN Company DescriptionsBioVie NASDAQ:BIVI$1.09 +0.06 (+5.83%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.13 +0.04 (+3.58%) As of 06/18/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.GlycoMimetics NASDAQ:GLYC$0.16 -0.01 (-6.63%) Closing price 06/13/2025Extended Trading$0.16 0.00 (0.00%) As of 06/13/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.NeuroSense Therapeutics NASDAQ:NRSN$2.45 +0.05 (+2.08%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$2.42 -0.03 (-1.02%) As of 06/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.Redwoods Acquisition NASDAQ:RWODRedwoods Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. In intends to focus on businesses in the carbon neutral and energy storage industries. The company was incorporated in 2021 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
